InterAx founder and CSO, Dr. Aurélien Rizk, discusses how we approach things differently and why it is crucial for the development of new therapies in the Dr. GPCR Podcast. I hope you enjoy listening to it! 🎤 https://lnkd.in/eVMe9Rx4 🎤
InterAx Biotech’s Post
More Relevant Posts
-
In our latest podcast episode, Chris Hughen sat down with Marc Surdyka, DPT, OCS to discuss the benefits and drawbacks of a test-retest approach, reactive versus proactive approaches to treatment and clinical decision making, setting realistic patient expectations, and much more. https://lnkd.in/gxZn44-j
-
🎙 New podcast episode! ➡️ Exploring Management Approaches for High-Sustained Anti-rhGAA IgG #Antibody Titers in Patients with #PompeDisease Listen and subscribe: https://lnkd.in/gcqqifZ7
-
🎙 New podcast episode! ✅ Investigating the Formation of New #BrainVascularMalformations in Patients with #HereditaryHemorrhagicTelangiectasia Listen and subscribe: https://lnkd.in/gUFxfGAA
-
Like Karen asks... How many sick days do you think the average person has? Especially for a clinical trial! On this episode we discuss what clinical research looks like, the value of representation in the numbers, and more. Comment your below if you've ever considered or experienced one. 🎙️ New podcast episode out now! Visit https://lnkd.in/eedJ8qQp for ways to stream
-
Founder of Color of Gastrointestinal Illnesses, Inc. | Award Winning 🏆 Health Advocate | Health Equity Architect
How we look at "sickness" impacts how we view many things. We've got work to do. Check out the latest episode of #CominInHOT on the Color of Gastrointestinal Illnesses, Inc. (COGI - Co-Gee) #youtube channel. This episode, titled #RespectTheTechnique is about why inclusion is necessary in the development of #clinicalresearch #clinicaltrials. So, #tunein
Like Karen asks... How many sick days do you think the average person has? Especially for a clinical trial! On this episode we discuss what clinical research looks like, the value of representation in the numbers, and more. Comment your below if you've ever considered or experienced one. 🎙️ New podcast episode out now! Visit https://lnkd.in/eedJ8qQp for ways to stream
-
Health Advances' Balazs Felcsuti participated in the first of Parexel’s five-part podcast series which explores business-critical decisions that take place at each stage of the drug development process. The first episode focuses on the #preclinical phase, and how #biotech sponsors should translate the science to clinical application and communicate this effectively to investors. Listen here: https://bit.ly/3KJZYZK #newproductplanning
Novel therapies often don’t meet their revenue expectations, but through informed decision-making, your company can minimize risk and maximize the probability of commercial success. In episode one of this podcast series, listen in as Paul Bridges moderates a discussion with clinical experts Jamie Kistler, Kristina Reeder, and Balazs Felcsuti on the critical decision points in the pre-clinical phase that can ultimately determine the success of your product. Create success by planning for it. Listen now: https://lnkd.in/gqtz4cD8 #ParexelBiotech #ClinicalDevelopment
-
-
Novel therapies often don’t meet their revenue expectations, but through informed decision-making, your company can minimize risk and maximize the probability of commercial success. In episode one of this podcast series, listen in as Paul Bridges moderates a discussion with clinical experts Jamie Kistler, Kristina Reeder, and Balazs Felcsuti on the critical decision points in the pre-clinical phase that can ultimately determine the success of your product. Create success by planning for it. Listen now: https://lnkd.in/gqtz4cD8 #ParexelBiotech #ClinicalDevelopment
-
-
Drug development is complex. There is competition, investors, complex regulations, HTA, etc. De-risking your drug development is key to success. This is one of several important podcasts for drug developers.
Novel therapies often don’t meet their revenue expectations, but through informed decision-making, your company can minimize risk and maximize the probability of commercial success. In episode one of this podcast series, listen in as Paul Bridges moderates a discussion with clinical experts Jamie Kistler, Kristina Reeder, and Balazs Felcsuti on the critical decision points in the pre-clinical phase that can ultimately determine the success of your product. Create success by planning for it. Listen now: https://lnkd.in/gqtz4cD8 #ParexelBiotech #ClinicalDevelopment
-
-
In the next episode of our podcast "Move Fast. Break Shit. Burn Out.", we talk with Ritu Kapur, Head of Digital Biomarkers at Verily, who talks about creating change. The theme throughout our conversation is about the need, skills, and support required to bring people along on the journey to manifest our vision. Stay tuned for the next episode. #CatalystMovement
-
Cytel experts Boaz Adler and Pierre COLIN discuss innovations in clinical trial design in a recent episode of the podcast Transformation in Trials. Be sure to give it a listen! https://lnkd.in/gKB5psXi
